Share class: WuXi AppTec Co., Ltd.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 38,70,76,150 0 0 69.28 %
Stock B 1 2,50,09,16,432 2,00,08,02,253 ( 80 %) 0

Major shareholders: WuXi AppTec Co., Ltd.

NameEquities%Valuation
20.93 %
53,57,11,396 20.93 % 7 501 M ¥
Temasek Holdings Pte Ltd. (Investment Management)
4.492 %
11,49,82,796 4.492 % 1 610 M ¥
Shanghai Zhongmin Yinfu Capital Management Co. Ltd.
3.402 %
8,70,74,568 3.402 % 1 219 M ¥
Summer Bloom Investments (I) Pte Ltd.
3.313 %
8,47,92,526 3.313 % 1 187 M ¥
China Asset Management Co., Ltd.
2.998 %
7,67,33,001 2.998 % 1 074 M ¥
Zhong Ou Asset Management Co., Ltd
2.868 %
7,33,93,875 2.868 % 1 028 M ¥
Huatai-PineBridge Fund Management Co., Ltd.
1.937 %
4,95,80,162 1.937 % 694 M ¥
Hwabao WP Fund Management Co., Ltd.
1.728 %
4,42,36,710 1.728 % 619 M ¥
China Merchants Fund Management Co., Ltd.
1.049 %
2,68,51,884 1.049 % 376 M ¥
China Southern Asset Management Co., Ltd.
0.9583 %
2,45,26,736 0.9583 % 343 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
NameEquities%Valuation
Qatar Holding LLC
6.871 %
3,50,75,300 6.871 % 490 M ¥
Invesco Asset Management Ltd.
3.753 %
1,91,56,800 3.753 % 268 M ¥
Fidelity Management & Research Co. LLC
3.557 %
1,81,58,767 3.557 % 254 M ¥
Schroder Investment Management (Hong Kong) Ltd.
3.229 %
1,64,85,600 3.229 % 230 M ¥
UBS Asset Management Switzerland AG
2.88 %
1,47,03,873 2.88 % 205 M ¥
FIAM LLC
2.314 %
1,18,11,680 2.314 % 165 M ¥
BlackRock Fund Advisors
2.195 %
1,12,04,075 2.195 % 157 M ¥
Qatar Investment Authority (Investment Management)
1.636 %
83,49,600 1.636 % 117 M ¥
BlackRock Advisors (UK) Ltd.
1.026 %
52,36,153 1.026 % 73 M ¥
Fidelity Management & Research (Hong Kong) Ltd.
0.9792 %
49,98,600 0.9792 % 70 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional152.53%
Individuals105.2%
Other33.67%

Based on 1000 largest holdings

Geographical origin of shareholders

China
111.79%
Individuals
105.21%
Singapore
39.53%
United States
8.99%
Qatar
8.51%
Hong Kong
6.19%
United Kingdom
5.96%
Switzerland
2.96%
Sweden
0.53%
Luxembourg
0.36%
Taiwan
0.36%
Malaysia
0.19%
Ireland
0.19%
Netherlands
0.14%
Japan
0.11%
Denmark
0.1%
Norway
0.07%
Australia
0.06%
Finland
0.04%
Canada
0.03%
France
0.02%
New Zealand
0.02%
Germany
0.02%
Austria
0.01%
Italy
0.01%
South Africa
0.01%

Based on 1000 largest holdings

Logo WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Employees
39,414
More about the company